Remove 2025 Remove Degenerative Disc Disease Remove Patients
article thumbnail

Spinal Stabilization Technologies™ Announces Enrollment of First U.S. Patient in IDE Trial for PerQdisc™ Nucleus Replacement Device

OrthoSpineNews

Spine Surgeon Dr. Frank Phillips Joins SST Board of Directors SAN ANTONIO, March 3, 2025 /PRNewswire/ — Spinal Stabilization Technologies, LLC (SST) has announced a significant milestone in its mission to revolutionize spinal care: the enrollment of the first U.S.

article thumbnail

Study Confirms Significant Clinical Benefit of Neo Medical’s Force Control Technology™ in Spinal Fusion Surgery

OrthoSpineNews

Yasser Abdalla , Head of Department of Neurosurgery, Nordwest-Krankenhaus, Sanderbusch (Germany), the study highlights the clear advantages of Neo’s platform in reducing early screw loosening and improving patient outcomes by managing unintended mechanical stress during surgery. Key Study Findings: 3.4x after one year 3.4

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data

OrthoSpineNews

May 13, 2025 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. MELVILLE, N.Y.,

article thumbnail

BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease

OrthoSpineNews

June 13, 2025 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. This data was shared at the prestigious ISSCR 2025 Annual Meeting in Hong Kong by Francisco Silva, Vice President of Research and Development. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc.

article thumbnail

BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

OrthoSpineNews

May 14, 2025 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. BioRestorative, BRTX or the Company) (NASDAQ: BRTX ) , a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the first quarter ended March 31, 2025 and provided an update on its business.

article thumbnail

Aurora Spine Corporation Announces Completion of Enrollment in Groundbreaking REFINE Study: First Prospective, Multi-Center, Multi-Specialty Study on Lumbar Interlaminar Fusion 

OrthoSpineNews

The REFINE study, designed to bridge the gap between conservative treatments and more invasive surgical options, has successfully enrolled its full cohort of patients across multiple centers in the United States. The data weve gathered is critical, its not just numbers, its the foundation for improving patient lives. CARLSBAD, Calif.,

article thumbnail

Global Spine, MIS and VCF Markets to Reach $38B by 2031, Fueled by Robotic Surgery, MIS Growth, and Next-Gen Implants – iData Research

OrthoSpineNews

VANCOUVER, BC,May 6, 2025/PRNewswire/ – New global reports on the Spine and Vertebral Compression Fracture (VCF) , along with Minimally Invasive Spine Surgery (MIS) markets, from iData Research reveal major shifts reshaping the industry. In parallel, minimally invasive spine surgery is gaining traction worldwide.